December 19
Paul J. Hastings Named CEO of QLT
PDF version
November 2
Novartis Ophthalmics and QLT Update Status of Visudyne™ Reimbursement Process
October 24
QLT Appoints Chief Financial Officer
QLT Announces Third Quarter Financial Results
October 19
Visudyne™ Therapy Reimbursement in U.S. Expanded to Include Patients with Occult Form of Wet Age-Related Macular Degeneration
October 11
QLT Announces Visudyne™ Sales for Third Quarter of 2001
October 1
QLT on Track to Meet Financial Targets
September 10
Novartis Ophthalmics and QLT File Canadian Submission for Expansion of Visudyne™ Approval
September 7
Novartis Ophthalmics and QLT File Submission with the European Medicines Agency to Expand the Use of Visudyne™ in AMD
September 5
QLT Appoints Vice President, Marketing & Sales Planning
August 23
Novartis Ophthalmics and QLT Announce FDA Approval of Visudyne™ as the First Drug Treatment for Pathologic Myopia and Ocular Histoplasmosis
August 13
QLT Expands Pipeline with Acquisition of Late-Stage Compound for Multidrug Resistance in Cancer
July 26
Novartis Ophthalmics and QLT Announce that Health Canada Approves Expanded Use of Visudyne™
July 25
QLT Announces Financial Results for Second Quarter and First Half of 2001
July 23
QLT and Novartis Ophthalmics to Fight Skin Cancer
June 7
QLT Enters into Research and License Agreement with Kinetek
May 10
Favorable Visudyne™ Clinical Results Published in American Journal of Ophthalmology Show Benefit in AMD Patients with Occult Disease
May 2
QLT Files Supplemental Claims Against Massachusetts Eye and Ear Infirmary in Ongoing Patent Litigation in Response to Issuance of New Patent
Vision Benefit Sustained During Third Year of Visudyne™ Therapy
April 25
QLT Announces First Quarter Financial Results
QLT Reviews Highlights from Annual General Meeting
April 19
QLT Announces Visudyne™ Sales for First Quarter of 2001
March 23
EU Commission Approves Expanded Use of Visudyne™
February 8
QLT Announces Fourth Quarter and Year End Results for 2000
February 7
Favorable Visudyne™ Clinical Results Announced for Occult AMD and Pathologic Myopia Patients
February 5
FDA Issues Approvable Letter for Expanded Use of Visudyne™
January 30
QLT Receives Notice of Lawsuit
